Compare Lithium Americas Corp (LAC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Mesoblast Limited — how do they compare? Lithium Americas Corp trades at $3.02 (market cap $1.01B), while Mesoblast Limited trades at $16.36 (market cap $2.17B). The key difference: Mesoblast Limited is far larger — about 2.1× Lithium Americas Corp's market cap, and Mesoblast Limited is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| LAC | MESO | |
|---|---|---|
Market Cap | $1.01B | $2.17B |
Sector | Basic Materials | Technology |
52-Week High | $10.05 | $20.96 |
52-Week Low | $2.55 | $12.88 |
Enterprise Value | $1.13B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.90, down 1.69% amid bearish technical signals despite recent earnings beats. The company shows negative profitability with ROE at -11.35% and net income of -$122.09M for 2025, though it maintains strong financing cash flow of $1.14B. Construction milestones at Thacker Pass project progress, with 2026 expected to be pivotal for operational developments according to company guidance.
Investment outlook balances significant project potential against substantial execution risks. While analyst consensus leans positive with 47% buy ratings and no sell recommendations, the stock faces headwinds from negative cash flow from operations and high capital expenditure requirements. Key risks include dilution from share issuances and sensitivity to lithium market dynamics.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
